CIPO Patents = 6 (Patent Applications = 6)

EPO Patents = 10 (Patent Applications = 1)

Average Co-Inventor Count = 4.2

ph-index = 4

Forward Citations = 55(Granted Patents)

Location History:

Foster City, CA (US) (2007 - 2008)
Belmont, CA (US) (2010)
San Mateo, CA (US) (2007 - 2014)
San Francisco, CA (US) (2011 - 2014)
Hayward, CA (US) (2015 - 2022)

Company Filing History:

Years Active: 2007-2022

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11497738 - Di-substituted pyrazole compounds for the treatment of diseases (2022-11-15),

2. 11339142 - Di-substituted pyrazole compounds for the treatment of diseases (2022-05-24),

3. 9133122 - Amide compounds, compositions and uses thereof (2015-09-15),

4. 8946439 - Amide compounds, compositions and uses thereof (2015-02-03),

5. 8859545 - Tetrahydronaphthyridine and tetrahydropyrido[4,3-D]pyrimidine compounds and compositions thereof useful for the treatment of inflammatory and respiratory diseases (2014-10-14),

6. 8779144 - Bicycloheteroaryl compounds as P2X7 modulators and uses thereof (2014-07-15),

7. 8653091 - Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof (2014-02-18),

8. 8546579 - [object Object] (2013-10-01),

9. 8093265 - Bicycloheteroaryl compounds as P2X7 modulators and uses thereof (2012-01-10),

10. 8076345 - 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof (2011-12-13),

11. 7816371 - [object Object] (2010-10-19),

12. 7745451 - Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions (2010-06-29),

13. 7576099 - Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same (2009-08-18),

14. 7414131 - Bicycloheteroarylamine compounds as ion channel ligands and uses thereof (2008-08-19),

15. 7402596 - Bicycloheteroaryl compounds as P2X7 modulators and uses thereof (2008-07-22),

Title: Innovations by John Kincaid in Medicinal Chemistry

Introduction

John Kincaid, a notable inventor based in San Mateo, CA, has made significant contributions to the field of medicinal chemistry, holding a total of 19 patents. His work primarily revolves around developing innovative compounds aimed at treating various diseases, showcasing his dedication to advancing healthcare solutions.

Latest Patents

Among his latest innovations are di-substituted pyrazole compounds designed for the treatment of diseases. These compounds, along with their pharmaceutical compositions, focus on addressing conditions associated with the abnormal activation of the SREBP pathway. This includes metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD). The patents represent a crucial step forward in potential therapeutic interventions for these widespread health issues, aligning with Formula (I) described in his patent filings.

Career Highlights

John Kincaid has had an impactful career, contributing to prestigious companies in the biopharmaceutical industry. He has worked with Renovis, Inc., and Evotec AG, where he played a vital role in several research and development projects. His innovative approach and expertise are evident in the patents he has filed, solidifying his status as a prominent inventor in the field.

Collaborations

Throughout his career, Kincaid has collaborated with distinguished professionals, including his coworkers Michael G. Kelly and Carl J. Kaub. These partnerships have enhanced his research endeavors, leading to the development of complex compounds that aim to tackle significant health challenges.

Conclusion

John Kincaid's innovative contributions to the biomedical field, particularly through his latest patents focused on di-substituted pyrazole compounds, underscore his commitment to improving healthcare treatments. His collaborations and experiences in leading companies highlight the collaborative effort required in the development of novel therapeutics, marking him as a key figure in the realm of medicinal chemistry.

This text is generated by artificial intelligence and may not be accurate.